Creative Medical Technology Receives IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

(24/7 MARKET NEWS) – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced, today, that it received Institutional Review Board (IRB) approval to proceed with its Clinical Trial for the treatment of Type 1 Diabetes with its CELZ-201 cell therapy. The FDA previously cleared its Investigational New Drug (IND) application within 30 days from submission.

Creative Medical Technology is at $1.04, up $0.5281 (+155.91%), on 7 million premarket shares.

Its 52-week trading range is $0.33 to $5.145. It’s blown through several resistance levels and trading at its May price levels. If can maintain the strong volume, its setup is favorable for a potential run to challenge the $2 resistance range.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist